Abstract of "Ethical Challenges with the Development of Biotechnology-Derived Allergy Therapeutics"
Bibliographic record
Abstract
Biotechnology-derived pharmaceuticals are a new generation of therapeutics that hold promise of providing novel treatments for disease. Among emerging biotech drugs, recombinant versions of allergen vaccines may replace varieties of lower-quality vaccines derived from natural sources, providing benefit in the treatment of allergy. However, along with this benefit, this presentation demonstrates that potential ethical challenges are emerging as these biotech allergy therapeutics approach commercialization. Many of these challenges pertain to novel possibilities for pharmaceutical companies to gain influence over the regulation of these drugs and monopolize their production. Allergen vaccines are used in immunotherapy where current therapeutics derived from natural sources are of less-than-ideal quality, stemming from variations in their potency and composition between batches. Current biotechnology methods provide means to raise the quality of these therapeutics through the isolation of allergen genes, such that the corresponding allergen protein may be produced consistently and homogeneously. While beneficial in production-related issues, our research identifies potential problems with these emerging biotech drugs. For one, these drugs require the development of novel quality and efficacy assessment procedures. Our research identifies that in certain cases pharmaceutical companies are the developers of such assessment procedures. We demonstrate how this situation is ethically problematic in terms of conflict of interest, where a company, rather than government regulators, gains undue control over determining the quality, safety, and efficacy of pharmaceuticals. We further note how the development of these drugs, in conjunction with their assessment methods, provides new opportunities for companies to submit multiple patents on their products. Thus, the possibility to produce generic versions of emerging allergen vaccines may be inhibited, providing pharmaceutical companies with unwarranted and prolonged production monopolies. This in turn inflates the cost of pharmaceuticals, which can inhibit their broad application in clinical practice. Overall, this presentation aims to exemplify the need for ethical assessments in biotech-drug development and regulation.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.023 | 0.038 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.006 | 0.010 |
| Scholarly communication | 0.013 | 0.008 |
| Open science | 0.002 | 0.005 |
| Research integrity | 0.009 | 0.019 |
| Insufficient payload (model declined to judge) | 0.014 | 0.005 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".